BQ-123 Sodium Salt

SKU
E-1032
  • CAS:136553-81-6
  • Formula:C31H42N6O7Na
  • MW:633.7 Da
  • Appearance:White solid
  • Purity:>99%

0

0

0

Product Name Qty
BQ-123.Sodium Salt
1 mg
$124.99
BQ-123.Sodium Salt
5 mg
$374.99

Description

BQ-123 is an antagonist of endothelin receptors that has been shown to exhibit rapid reversibility. Research surrounding BQ-123 has focused heavily on its potential application as a novel anticancer drug, owing to its proven ability to inhibit binding of the overexpressed endothelin-1 that is associated with various cancers. Rat studies have provided in vivo evidence that BQ-123 can actively reduce tumor load. The compound has also been studied for its ability to affect ischemic arrhythmia in rat models. Intriguingly, the nature of this effect is highly dependent on dosage, with certain low dosages successfully attenuating arrhythmias and higher dosages actively exacerbating them.

More Information
Alternate Name/Synonyms
BQ123, ETA-Receptor Antagonist; Cyclo (D-Trp-D-Asp-Pro-D-Val-Leu); Endothelin Receptor A Antagonist BQ-123
SKU
E-1032
CAS #
136553-81-6
Chemical Name
2-[(3R,6R,9S,12R,15S)-6-(1H-indol-3-ylmethyl)-9-(2-methylpropyl)-2,5,8,11,14-pentaoxo-12-propan-2-yl-1,4,7,10,13-pentazabicyclo[13.3.0]octadecan-3-yl]acetic acid
Chemical Formula
C31H42N6O7Na
Molecular Weight
633.7 Da
Appearance
White solid
Purity
>99%
Solubility
Soluble in DMSO or water
Melting Point
N/A
Preparation
N/A
Storage Temp
-20ºC
THERAPEUTIC AREA
Epilepsy, Preterm birth
USE
BQ-123 reduces ischemia-induced ventricular arrhythmia in a rat model. It prevents LPS-induced preterm birth in mice via the induction of uterine and placental IL-10, and it decreases IL-1β and TNFα in the placenta while also decreasing transcription of ET-1 in the uterus.
Merck Index
N/A
RTECS
N/A
Handling
Provide appropriate exhaust ventilation at places where dust is formed.
Certificate of Analysis 1
Certificate of Analysis 2
Certificate of Analysis 3
Handling Provide appropriate exhaust ventilation at places where dust is formed.
To Top